Trius Therapeutics, Bayer Form Strategic Collaboration to Develop Torezolid Phosphate in Asia-Pacific and Emerging Markets

Trius Therapeutics and Bayer announced they have signed an exclusive agreement to develop and commercialize Trius’ lead Phase III antibiotic, torezolid phosphate (torezolid), in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East, excluding North and South Korea.
MarketWatc